Filing Details
- Accession Number:
- 0001628280-23-003923
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-16 16:54:22
- Reporting Period:
- 2023-02-14
- Accepted Time:
- 2023-02-16 16:54:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1933414 | Mineralys Therapeutics Inc. | MLYS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1253170 | Srinivas Akkaraju | 628 Middlefield Road Palo Alto CA 94301 | Yes | No | Yes | No | |
1699737 | Samsara Biocapital, L.p. | 628 Middlefield Road Palo Alto CA 94301 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-02-14 | 3,581,861 | $0.00 | 3,581,861 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2023-02-14 | 937,500 | $16.00 | 4,519,361 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2023-02-14 | 2,135,504 | $0.00 | 2,135,504 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2023-02-14 | 1,446,357 | $0.00 | 1,446,357 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.
- Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.